Published Date:2024-08-07 Original Link:https://www.onenessbio.com/en/news_detail309_2.htm No 1 Date of announcement 2024/08/07 Time of announcement 20:05:43 Subject Fespixon has passed the preliminary review by the National Healthcare Security Administration of China To which item it meets paragraph 53 Date of events 2024/08/07 Statement Date of occurrence of the event: 2024/08/07 Company name: ONENESS BIOTECH CO., LTD. Relationship...Read More
Published Date:2024-08-06 Original Link:https://www.onenessbio.com/en/news_detail308_2.htm No 1 Date of announcement 2024/08/06 Time of announcement 21:25:12 Subject Fespixon, the new drug in treatment of diabetic foot ulcers has been approved by Indonesia BPOM and the drug license will be collected To which item it meets paragraph 10 Date of events 2024/08/06 Statement Date of occurrence of the...Read More
Published Date:2024-08-02 Original Link:https://www.onenessbio.com/en/news_detail307_2.htm No 1 Date of announcement 2024/08/02 Time of announcement 17:21:12 Subject Announcement of the date of the Company’s board of directors meeting for the Second Quarter of 2024 Consolidated Financial Reports To which item it meets paragraph 31 Date of events 2024/08/02 Statement Date of a notice of the board of...Read More
Published Date:2024-07-25 Original Link:https://www.onenessbio.com/en/news_detail306_2.htm No 1 Date of announcement 2024/07/25 Time of announcement 19:37:02 Subject Fespixon has been included in CSE Expert consensus on wound treatment of diabetic foot ulcer (2024). The health economics analysis supports its cost-effectiveness. To which item it meets paragraph 53 Date of events 2024/07/25 Statement Date of occurrence of the...Read More
Published Date:2024-07-22 Original Link:https://www.onenessbio.com/en/news_detail305_2.htm No 1 Date of announcement 2024/07/22 Time of announcement 20:44:43 Subject The EU MDR application of Bonvadis for acute and chronic wounds and scar management has been accepted by EU Notified Body for QMS and product certification. To which item it meets paragraph 10 Date of events 2024/07/22 Statement Date of...Read More
Published Date:2024-07-21 Original Link:https://www.onenessbio.com/en/news_detail304_2.htm No 1 Date of announcement 2024/07/21 Time of announcement 22:40:52 Subject Oneness and Microbio (Shanghai) have entered into an exclusive agreement of Fespixon commercialization with China Resources Double Crane Pharmaceutical Co., Ltd. To which item it meets paragraph 10 Date of events 2024/07/19 Statement Date of occurrence of the event: 2024/07/19...Read More
Published Date:2024-07-09 Original Link:https://www.onenessbio.com/en/news_detail303_2.htm No 1 Date of announcement 2024/07/09 Time of announcement 17:51:01 Subject Announced The Board of Directors’ resolution of 2024 that the related matters of ex-dividend. To which item it meets paragraph 14 Date of events 2024/07/09 Statement Date of the resolution by the board of directors or shareholders’ meeting, or of...Read More
Published Date:2024-07-02 Original Link:https://www.onenessbio.com/en/news_detail302_2.htm No 1 Date of announcement 2024/07/02 Time of announcement 18:14:58 Subject Fespixon is included in the “DAROC Clinical Practice Guidelines For Type 2 Diabetes Care 2022” (2024 update) To which item it meets paragraph 53 Date of events 2024/07/02 Statement Date of occurrence of the event: 2024/07/02 Company name: ONENESS BIOTECH...Read More
Published Date:2024-06-28 Original Link:https://www.onenessbio.com/en/news_detail301_2.htm No 1 Date of announcement 2024/06/28 Time of announcement 20:54:59 Subject With its medical device clearance by the FDA for partial-thickness wounds, Oneness has decided to discontinue ON101CLCT04 Ph3 clinical trial in the US To which item it meets paragraph 10 Date of events 2024/06/28 Statement Date of occurrence of the...Read More
